Merck (MRK), AstraZeneca (AZN) Report Update on Phase 3 GY004 for Cediranib & LYNPARZA (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/3/2026

1. KRG
2. META
3. CCHGY
4. PRY:IM
5. PRYMY
6. SPY
7. SKA-B
8. ALAR
9. CCH:LN
10. DRT-DBA

Go back to Merck (MRK), AstraZeneca (AZN) Report Update on Phase 3 GY004 for Cediranib & LYNPARZA (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 2,379,659       

Merck & Co. (NYSE: MRK) Delayed: 129.56 +4.19 (3.34%)
Previous Close $125.37    52 Week High $65.46 
Open $126.18    52 Week Low $47.97 
Day High $129.61    P/E 88.14 
Day Low $125.99    EPS $1.47 
Volume 7,833,992